# Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

Source: https://onco.cc/trials/nct04153734/  
OnCo record `nct04153734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, carboplatin, pemetrexed and nab-paclitaxel in lung cancer, run by Kobe Minimally Invasive Cancer Center, not yet recruiting.

## Summary

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC is a phase 2, interventional study registered as NCT04153734 by Kobe Minimally Invasive Cancer Center, with a registry enrolment figure of 21 participants, started 2019-12-01 and due to reach its primary completion in 2021-11-30. Interventions recorded: Pembrolizumab; Cis Platinum; Carboplatin; Pemetrexed; nab paclitaxel. Conditions listed: Locally Advanced Non-small Cell Lung Cancer. Primary outcome: 2-year PFS rate. Lung eligibility wording from the registry: "Histologically confirmed NSCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: Evolution
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04153734
- Phase: 2
- Setting: Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study
- Sponsor: Kobe Minimally Invasive Cancer Center
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT04153734: https://clinicaltrials.gov/study/NCT04153734

## Connected records

- cancers: [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04153734.json